CGTX on Nasdaq
COGNITION THERAPEUTICS INC
Price unavailable
Last updated Oct 16, 2026.
Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement in the latest annual report, as filed.7
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Research and development | $37.2M | $41.7M |
| General and administrative | $10.6M | $12.3M |
| Total operating expenses | $47.8M | $54.0M |
| Loss from operations | -$47.8M | -$54.0M |
| Grant income | $23.4M | $19.5M |
| Other income, net | $919.0K | $666.0K |
| Interest expense | -$13.0K | -$25.0K |
| Loss on currency translation from liquidation of subsidiary | -$195.0K | |
| Total other income, net | $24.3M | $20.0M |
| Net loss | -$23.5M | -$34.0M |
| Foreign currency translation adjustment, including reclassifications | $195.0K | |
| Total comprehensive loss | -$23.5M | -$33.8M |
| Net loss per share, basic (in dollars per share) | -$0.32 | -$0.86 |
| Net loss per share, diluted (in dollars per share) | -$0.32 | -$0.86 |
| Weighted-average common shares outstanding, basic (in shares) | 72.8M shares | 39.7M shares |
| Weighted-average common shares outstanding, diluted (in shares) | 72.8M shares | 39.7M shares |
Every line of the balance sheet in the latest annual report, as filed.7
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $36.8M | $25.0M | |
| Grant receivables | $9.9M | $2.7M | |
| Prepaid expenses and other current assets | $1.1M | $1.9M | |
| Restricted cash equivalents | $190.0K | ||
| Total current assets | $48.0M | $29.6M | |
| Property and equipment, net | $93.0K | $181.0K | |
| Right-of-use assets, operating leases | $306.0K | $498.0K | |
| Total assets | $48.4M | $30.2M | |
| Accounts payable | $1.1M | $2.0M | |
| Accrued expenses | $12.0M | $7.6M | |
| Deferred grant income, current | $367.0K | $1.1M | |
| Operating lease liabilities, current | $136.0K | $193.0K | |
| Other current liabilities | $307.0K | $279.0K | |
| Total current liabilities | $13.9M | $11.1M | |
| Operating lease liabilities, non-current | $195.0K | $342.0K | |
| Total liabilities | $14.1M | $11.5M | |
| Common stock, $0.001 par value, 250,000,000 shares authorized; 88,904,161 and 59,854,877 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | $90.0K | $60.0K | |
| Additional paid-in capital | $232.8M | $193.8M | |
| Accumulated deficit | -$198.6M | -$175.2M | |
| Total stockholders' equity | $34.3M | $18.8M | $24.5M |
| Total liabilities and stockholders' equity | $48.4M | $30.2M | |
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Preferred stock shares authorized | 10.0M shares | 10.0M shares | |
| Preferred stock, shares issued | 0 shares | 0 shares | |
| Preferred stock, shares outstanding | 0 shares | 0 shares | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized | 250.0M shares | 250.0M shares | |
| Common stock, shares issued | 88.9M shares | 59.9M shares | |
| Common stock, shares outstanding | 88.9M shares | 59.9M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.7
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$23.5M | -$34.0M |
| Depreciation and amortization | $36.0K | $107.0K |
| Equity-based compensation | $2.1M | $3.7M |
| Amortization of right-of-use assets | $192.0K | $159.0K |
| Loss on currency translation from liquidation of subsidiary | $195.0K | |
| Realized loss on sale of property and equipment | $41.0K | |
| Grant receivables | -$7.2M | -$1.4M |
| Prepaid expenses and other assets | $1.2M | $1.6M |
| Accounts payable and accrued expenses | $3.5M | $1.9M |
| Deferred grant income and other liabilities | -$699.0K | -$635.0K |
| Operating lease liabilities | -$204.0K | -$159.0K |
| Net cash used in operating activities | -$24.6M | -$28.5M |
| Payments for property and equipment | -$4.0K | |
| Proceeds from sale of property and equipment | $9.0K | |
| Net cash used in investing activities | $9.0K | -$4.0K |
| Proceeds from the exercise of common stock options | $71.0K | $82.0K |
| Payment of employee withholding taxes on vested restricted stock units | -$164.0K | -$128.0K |
| Payments on loan payable | -$353.0K | -$739.0K |
| Net cash provided by financing activities | $36.6M | $23.6M |
| Net increase (decrease) in cash, cash equivalents, and restricted cash equivalents | $12.0M | -$4.9M |
| Prepayment of insurance through third-party financing | $381.0K | $475.0K |
Former names
- COGNITION THERAPUTICS INCJan 29, 2009 to Dec 28, 20102
Recent filings
- Aug 7, 202610-Q
- Aug 6, 20268-K
- Jun 24, 20268-K
- Jun 22, 20264 PRIMARY DOCUMENT
- Jun 22, 20264 OWNERSHIP DOCUMENT
- Jun 22, 20264 OWNERSHIP DOCUMENT
- Jun 22, 20264 OWNERSHIP DOCUMENT
- Jun 22, 20264 OWNERSHIP DOCUMENT
- Jun 18, 20268-K
- Jun 4, 20268-K
- May 21, 20268-K
- May 8, 202610-Q
- May 7, 20268-K
- May 4, 20264 OWNERSHIP DOCUMENT
- Apr 27, 2026DEF 14A
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9